NCT07517419Enrolling by invitationPhase 2
PIPAC in Gastric Peritoneal Metastasis
Pressurized IntraPeritoneal Aerosol Chemotherapy With Cisplatin and Doxorubicin (PIPAC) in Gastric Peritoneal Metastasis: A Feasibility Study
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
This is a pilot study aiming at evaluating the effects of PIPAC with Doxorubicin + Cisplastin on patients with PM of gastric cancer. All patients who are diagnosed with gastric cancer with peritoneal metastases in the Prince of Wales Hospital (PWH), HK will be screened for eligibility. There are two aims for this study: 1. To evaluate safety and efficacy of the procedure together with postoperative outcomes and long term overall and progression free survival. 2. Aim at obtaining tissue samples for molecular analysis and for potential tissue organoids and biobank.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 11 Mar 2026
- Start date
- 11 Oct 2021
- Primary completion date
- 28 Feb 2031
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07517419
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 11 Oct 2021 to the primary completion date, 28 Feb 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- HER2+++ tumor with indicated for Trastuzumab therapy
- Any laparotomy during 3 months before inclusion. (Laparoscopy is not an exclusion criterium)
- Contraindicated to any drug contained in the chemotherapy regimen
- Concomitant intraperitoneal chemotherapy, immunotherapy or target therapy
Other illness
- Extraperitoneal metastases including liver metastases and malignant pleural effusion. The presence of suspicious retroperitoneal lymph nodes is not an exclusion criterium.
- Active infectious (bacterial, viral) disease. Elevated CRP with no identified focus is not an exclusion criterium
Other
- Patients with adenocarcinoma of Siewart I
- Bowel obstruction, not tolerating oral diet
- Pregnancy or breastfeeding
Who the study is looking for
- Patients age \>= 18, \<= 80 years old
- Performance status (WHO) \<=2
- Histologically evidenced synchronous PM of gastric adenocarcinoma cancer
- Peritoneal Cancer Index (PCI) score \> 8, or \<=8 and patient not fit for cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (CRS + HIPEC)
- Patients with isolated ovarian metastasis could be included
- White blood cells \>3.5000/mm3; neutrophils \> 1.500/mm3; platelets \>100,000/mm3
- Creatinine \<1.5mg/dL and creatinine clearance \>60ml/min and serum total bilirubin \<2mg/dL
- Ability to give written consent prior to commencement of treatment
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Chinese University of Hong Kong, Shatin, HK Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.